Early Biomarkers as Predictors of Nephrology Trial Trajectory
Faced with slow-moving study endpoints and distant clinical thresholds, nephrology sponsors need earlier, actionable insights to support critical development decisions and major investment milestones. This article explores how biomarkers are reshaping nephrology research, examining the established strategies, emerging tools, and missed opportunities that can accelerate timelines and reduce ambiguity.
